Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: CXCL8

Summary for CXCL8

Gene information	Gene symbol	CXCL8
	Ensembl ID	ENSG00000169429
	Entrez ID	3576
	Gene name	C-X-C motif chemokine ligand 8
	Synonyms	3-10C\|AMCF-I\|b-ENAP\|GCP-1\|GCP1\|IL-8\|IL8\|K60\|LECT\|LUCT\|LYNAP\|MDNCF\|MONAP\|NAF\|NAP-1\|NAP1\|SCYB8\|TSG-1
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: CXCL8

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	0.300266	4.21e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.376122	4.43e-19
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.670477	4.37e-06
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.441983	1.18e-15
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Malignant cells	-0.303781	9.67e-04
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	Mono/Macro	-0.761272	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	1.12149	1.91e-17
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	1.47618	1.24e-28
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	-1.1759	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	1.32395	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-1.45249	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-1.3432	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.379874	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.271844	2.27e-09
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-1.80697	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	cDCs	-0.899478	2.34e-02
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	-0.963069	2.22e-18
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.997544	2.15e-02
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	2.15519	0.00e+00

Top

Expression of CXCL8 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to CXCL8

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Gene symbol	Cell type with DEG	Interaction ID	Interacting pair	Gene A	Gene B	Integrin	Interacting cell type1	Interacting cell type2	Dataset	Timepoint	Condition
CXCL8	Mono/Macro	CPI-SS0911EECCC	CXCL8_ACKR1	CXCL8	ACKR1	False	Mono/Macro	Erythrocytes	GSE189460	pre	resistant
CXCL8	Mono/Macro	CPI-SS0911EECCC	CXCL8_ACKR1	CXCL8	ACKR1	False	Mono/Macro	Erythrocytes	GSE189460	pre	sensitive
CXCL8	Malignant cells	CPI-SS0911EECCC	CXCL8_ACKR1	CXCL8	ACKR1	False	Malignant cells	Erythrocytes	GSE199333	post	sensitive
CXCL8	Malignant cells	CPI-SS0911EECCC	CXCL8_ACKR1	CXCL8	ACKR1	False	Malignant cells	Erythrocytes	GSE199333	pre	resistant
CXCL8	Malignant cells	CPI-SS0911EECCC	CXCL8_ACKR1	CXCL8	ACKR1	False	Malignant cells	Erythrocytes	GSE199333	pre	sensitive
CXCL8	Neutrophils	CPI-SS0315F51DD	CXCL8_CXCR2	CXCL8	CXCR2	False	Malignant cells	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0698C4DC4	CXCL8_CXCR1	CXCL8	CXCR1	False	Malignant cells	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0315F51DD	CXCL8_CXCR2	CXCL8	CXCR2	False	Mast cells	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Mono/Macro	CPI-SS0911EECCC	CXCL8_ACKR1	CXCL8	ACKR1	False	Mono/Macro	Endothelial cells	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0698C4DC4	CXCL8_CXCR1	CXCL8	CXCR1	False	Mast cells	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Mono/Macro	CPI-SS0698C4DC4	CXCL8_CXCR1	CXCL8	CXCR1	False	Mono/Macro	NK cells	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0315F51DD	CXCL8_CXCR2	CXCL8	CXCR2	False	Mono/Macro	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Mono/Macro	CPI-SS0315F51DD	CXCL8_CXCR2	CXCL8	CXCR2	False	Mono/Macro	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0698C4DC4	CXCL8_CXCR1	CXCL8	CXCR1	False	Mono/Macro	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Mono/Macro	CPI-SS0698C4DC4	CXCL8_CXCR1	CXCL8	CXCR1	False	Mono/Macro	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0911EECCC	CXCL8_ACKR1	CXCL8	ACKR1	False	Neutrophils	Endothelial cells	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0315F51DD	CXCL8_CXCR2	CXCL8	CXCR2	False	Neutrophils	NK cells	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0698C4DC4	CXCL8_CXCR1	CXCL8	CXCR1	False	Neutrophils	NK cells	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0315F51DD	CXCL8_CXCR2	CXCL8	CXCR2	False	Neutrophils	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0698C4DC4	CXCL8_CXCR1	CXCL8	CXCR1	False	Neutrophils	Neutrophils	GSE207422_Tor	post	resistant
CXCL8	Neutrophils	CPI-SS0911EECCC	CXCL8_ACKR1	CXCL8	ACKR1	False	Neutrophils	Endothelial cells	GSE207422_Tor	post	sensitive
CXCL8	Neutrophils	CPI-SS0315F51DD	CXCL8_CXCR2	CXCL8	CXCR2	False	Neutrophils	NK cells	GSE207422_Tor	post	sensitive
CXCL8	Neutrophils	CPI-SS0698C4DC4	CXCL8_CXCR1	CXCL8	CXCR1	False	Neutrophils	Neutrophils	GSE207422_Tor	post	sensitive
CXCL8	Neutrophils	CPI-SS0315F51DD	CXCL8_CXCR2	CXCL8	CXCR2	False	Neutrophils	Neutrophils	GSE207422_Tor	post	sensitive

Page: 1

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
CXCL8	Epigenetic Alteration of DNA, RNA or Protein
CXCL8	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating CXCL8

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
CXCL8	hsa-miR-5692a	99.764	NM_000584
CXCL8	hsa-miR-140-3p	93.8253	NM_000584
CXCL8	hsa-miR-3671	92.221	NM_000584
CXCL8	hsa-miR-548at-5p	91.7357	NM_000584
CXCL8	hsa-miR-153-5p	88.823	NM_000584
CXCL8	hsa-miR-4699-3p	87.7327	NM_000584
CXCL8	hsa-miR-4436b-5p	86.6828	NM_000584
CXCL8	hsa-miR-2115-3p	85.295	NM_000584
CXCL8	hsa-miR-4782-5p	84.9028	NM_000584
CXCL8	hsa-miR-5706	84.9028	NM_000584
CXCL8	hsa-miR-4312	84.5508	NM_000584
CXCL8	hsa-miR-545-5p	83.8214	NM_000584
CXCL8	hsa-miR-4687-3p	83.1688	NM_000584
CXCL8	hsa-miR-607	82.809	NM_000584
CXCL8	hsa-miR-6732-3p	81.6378	NM_000584
CXCL8	hsa-miR-1294	81.4523	NM_000584
CXCL8	hsa-miR-9986	81.4523	NM_000584
CXCL8	hsa-miR-493-5p	81.0425	NM_000584
CXCL8	hsa-miR-376a-2-5p	80.2164	NM_000584

Page: 1

Top

Motifs and transcription factors (TFs) regulating CXCL8

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
CXCL8	transfac_pro__M08794	PRDM16 (directAnnotation).
CXCL8	transfac_pro__M06177	ZNF41 (directAnnotation).
CXCL8	taipale_tf_pairs__ERF_TBX21_TMACACCGGAAG_CAP	ERF; TBX21 (directAnnotation).
CXCL8	taipale_tf_pairs__HOXC10_TBX21_TMRCACYTMATWAA_CAP_repr	HOXC10; TBX21 (directAnnotation).
CXCL8	kznf__ZFP1_Isakova2017.1_SMiLE-seq	ZFP1 (directAnnotation).
CXCL8	metacluster_52.4	ZNF276; ZNF276 (directAnnotation). ZSCAN21 (inferredBy_Orthology).
CXCL8	kznf__ZIM2_Imbeault2017_OM_MEME	ZIM2 (directAnnotation).
CXCL8	transfac_pro__M01722	RORB (directAnnotation).
CXCL8	taipale_cyt_meth__POU6F1_NTAATKAGSN_FL_meth	POU6F1 (directAnnotation).
CXCL8	metacluster_190.2	NFATC1; NFATC1; NFATC2; NFATC2 (directAnnotation).
CXCL8	tfdimers__MD00344	HOXA13 (directAnnotation).
CXCL8	transfac_pro__M06473	ZNF440 (directAnnotation).
CXCL8	metacluster_178.16	ZNF660; ZNF660 (directAnnotation).
CXCL8	transfac_pro__M06724	ZNF331 (directAnnotation).
CXCL8	swissregulon__hs__SOX9	SOX9 (directAnnotation).
CXCL8	transfac_pro__M06231	ZNF273 (directAnnotation).
CXCL8	transfac_pro__M05542	SNAPC4 (directAnnotation).
CXCL8	metacluster_20.7	EN2; EN2 (directAnnotation).
CXCL8	transfac_pro__M05475	ZBTB41 (directAnnotation).
CXCL8	transfac_pro__M05686	ZNF141 (directAnnotation).
CXCL8	tfdimers__MD00315	NKX3-2; OTX1; OTX2 (directAnnotation).
CXCL8	tfdimers__MD00433	NKX3-2; ZNF217 (directAnnotation).
CXCL8	taipale_tf_pairs__ETV2_TBX21_TMACACMGGAARN_CAP	ETV2; TBX21 (directAnnotation).
CXCL8	metacluster_20.2	BARHL2; BARHL2 (directAnnotation).
CXCL8	metacluster_35.5	ELF1; ELF2; ELF3; ELF3; ELK1; ELK4; ERF; ERG; ETS1; ETS1; ETS2; ETV7; ETV7; FLI1; FLI1 (directAnnotation).
CXCL8	tfdimers__MD00358	FOXA1; HLTF (directAnnotation).
CXCL8	tfdimers__MD00602	MYB; STAT6 (directAnnotation).
CXCL8	transfac_pro__M06783	ZNF443 (directAnnotation).
CXCL8	taipale_tf_pairs__FLI1_DLX2_ACCGGAARTNNNYAATTA_HT	DLX2; FLI1 (directAnnotation).
CXCL8	jaspar__MA0642.2	EN2 (directAnnotation).
CXCL8	homer__GGAAATTCCC_NFkB-p65-Rel	RELA (inferredBy_Orthology).
CXCL8	metacluster_22.27	NFE2L2 (inferredBy_Orthology).
CXCL8	transfac_pro__M06577	ZNF594 (directAnnotation).
CXCL8	metacluster_84.12	RARB; RARG (directAnnotation).
CXCL8	metacluster_27.14	ZFP1; ZFP1 (directAnnotation).
CXCL8	transfac_pro__M05884	ZNF439 (directAnnotation).
CXCL8	transfac_pro__M06346	E4F1 (directAnnotation).
CXCL8	transfac_pro__M04966	EP300 (directAnnotation).
CXCL8	metacluster_161.37	EN1 (directAnnotation).
CXCL8	metacluster_161.41	EVX1 (directAnnotation).
CXCL8	metacluster_161.54	HOXA5 (directAnnotation).
CXCL8	metacluster_32.28	ZFP28 (directAnnotation).
CXCL8	transfac_pro__M05411	ZNF784 (inferredBy_Orthology).
CXCL8	transfac_public__M00291	FOXC1 (directAnnotation).
CXCL8	transfac_pro__M01234	PDX1 (directAnnotation).
CXCL8	swissregulon__hs__ELF2	ELF2 (directAnnotation).
CXCL8	kznf__ZNF614_Imbeault2017_RP_ChIP-seq	ZNF614 (directAnnotation).
CXCL8	swissregulon__hs__SPI1	SPI1 (directAnnotation).
CXCL8	hdpi__ZNF205	ZNF205 (directAnnotation).
CXCL8	tfdimers__MD00515	ARID3A; KLF4 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
CXCL8	"ABT-510"	DB05434	small molecule
CXCL8	"MDX-018"	DB05484	small molecule
CXCL8	"Oleandrin"	DB12843	small molecule
CXCL8	"Rivanicline"	DB05855	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."